This webinar has already taken place. However, you can watch a recording of it by clicking on the screen shot just below.
Originally aired on October 16th, 2015
FREE take-away: To know more about this technology, please download the PDF here.
One Million Solutions in Health™ has established a one-of-a-kind, new partnership with the United States’ National Institutes of Health Office of Technology Transfer (NIH-OTT) and the National Cancer Institute Technology Transfer Center (NCI-TTC) to increase awareness and understanding of NIH technologies by potential partners in the life science and healthcare industries.
This provides you with a front-row seat to hear about new technology and science from various scientists at the NIH.
Soon, this opportunity to learn directly from a number of NIH scientists, will ONLY be made available to members of our Technology Evaluation Consortium™ (TEC). But, for the next few months, this information is being shared beyond our current membership, to provide you and/or your organization with the opportunity to join the consortium.
This is also your opportunity to participate in our exclusive Signature Square™ process, where end-users rate and evaluate the technology, providing feedback directly to the scientist, to help effect and drive the NIH research Road Map for this technology.
This groundbreaking discovery features five small molecules that lower mutant huntingtin protein (HTT) in primary cells from Huntington’s, Alzheimer’s and Parkinson’s patients and a cell culture model for Huntington’s disease. These target a major strategy in the treatment of these diseases in a new and unique way. These small molecules were discovered based on their ability to induce autophagy, a cellular process whereby components of the cytoplasm are degraded. Current progress in the autophagy and Huntington’s disease fields show that autophagy induction in in vitro and in vivo models, lowers mutant HTT protein and improves disease symptoms, making autophagy induction a promising strategy for treating Huntington’s disease, and potentially Alzheimer’s and Parkinson’s disease patients.
Current member companies in the Signature Square program include organizations like Pfizer, AbbVie, Amgen and Janssen, along with many others. However, on a trial basis, we are allowing new industry participants, and other scientists, clinicians & organizations to evaluate this technology and take part in this webinar entitled “Groundbreaking Molecules that will Revolutionize Autophagy Induction for Treating Huntington’s Disease, and potentially Alzheimer’s and Parkinson’s Diseases” on Friday, October 16th at 11am EST.
Currently, there is a need for safe and effective inducers of autophagy for patients. More importantly, there is no cure for Huntington’s, Alzheimer’s or Parkinson’s — with the current treatment only targeting the minimization of symptoms. Due to the large unmet need of effective treatment options for these types of patients, and the promise of autophagy induction as a therapeutic strategy, this technology holds an enormous value.
Dr. Lori Griner
Post-doctoral Research Fellow
Dr. Melvin L. DePamphilis
Dawn Van Dam
President & CEO
One Million Solutions in Health™